China CAS:595-33-5 Manufacturer

October 2021
API China is a well-established comprehensive pharmaceuticals and chemicals show in Chinese pharmaceutical industry. With more than 40 years’ experience in China, it has been a well-known celebration for all parties involved in Chinese Pharmaceutical market.

CPhI is the undisputed leader in the pharmaceutical industry. CPhI China offers a key access point to the second largest pharma market in the world. The exhibition features over 3,000 companies and incorporates various API showcases like bioLIVE, iCSE, NEX and FDF, creating a comprehensive platform that connects the entire pharmaceutical industry chain in the Asian-Pacific region.

Gedian Humanwell is a modern high-tech pharmaceutical company specializing in the R&D, production and sales of fertility regulation drugs and steroidal APIs. Our team will be at API Hall, booth 81B40, welcome to visit us!

In 2024, CPhI China will continue to be a unique opportunity for global pharmaceutical companies, manufacturers and suppliers. We will be waiting for you at the W1G20 booth on time to explore and interpret new trends in the pharmaceutical industry and interact with each other to further expand their business cooperation and various business opportunities. See you in Shanghai!

I've spent over twenty years working with companies like yours, and if there's one question I hear more than any other, it's this one. Selecting the right intermediates can feel like a high-stakes puzzle, where one wrong piece can impact your entire production line. It’s a decision that goes beyond mere cost; it's about partnership, reliability, and the integrity of your final product. In my journey, I've seen how a strategic partnership with a focused manufacturer like Humanwell Pharmaceutical can transform this challenging task from a source of anxiety into a competitive advantage. Let's break down the critical parameters you need to consider.

When buyers search for dependable pharmaceutical raw material partners, they often focus on price, lead time, and product availability first. In my experience, that approach can overlook a more important signal: how a supplier structures its APIs Category.